Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(1.04) per share which met the analyst consensus estimate. This is a 60 percent decrease over losses of $(0.65) per share from the same period last year. The company reported $10.00 thousand in sales this quarter. This is a 69.70 percent decrease over sales of $33.00 thousand the same period last year.
Lumos Pharma Q2 EPS $(1.04), Inline, Sales $10.00K Down From $33.00K YoY
Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(1.04) per share which met the analyst consensus estimate. This is a 60 percent decrease over losses of $(0.65) per share from the same period last year. The
